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MOLECULAR ASPECTS OF THE BONE METASTASTASES 
DEVELOPMENT IN PROSTATE CANCER. 
 
This review is devoted to the topical issue of modern medicine – the 
molecular mechanisms and factors for the development of bone metastases 
of malignant tumors, in particular prostate cancer. The recent publication 
on the formation and progression of prostate cancer bone metastases were 
analyzed in this study.  
The expression of some molecular markers in tumor and metastatic 
tissue and their role in tumor progression were also analyzed in this study. 
A common concept for the development of specific metastases is a seed 
and soil theory. According to this concept, circulating cancer cells 
recognize some organs as the optimal microenvironment for their 
development. However, the molecular mechanisms of this phenomenon 
remain unknown. 
Molecular and genetic features of the androgen receptors expression in 
the tumor and their role in metastatic tissue were summarized and 
compared in this study. We also demonstrated the effect of these receptors 
on the development of osteoblastic metastases and castration-resistant 
prostate cancer. Authors analyzed and summarized data about the role of 
p53 protein, Bax and activated caspase 3 in apoptosis, mechanisms of 
neoangiogenesis and remodeling of tumor connective tissue with matrix 
metalloproteinase 1, the presence of collagen type I and osteonectin in 
neoplastic tissues and the role of inflammation in metastasis development. 
Functions of heat shock proteins with molecular masses of 70 and 90 kDa 
and their role in tumor and metastatic tissue were also analyzed. Thus, the 
study complements and summarizes the data on the development of bone 
metastases of prostate cancer. The study analyzed the molecular 
characteristics of prostate cancer during its metastatic spread. 
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androgen receptors, neoangiogenesis, heat shock proteins, matrix 
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МОЛЕКУЛЯРНІ ОСОБЛИВОСТІ РОЗВИТКУ КІСТКОВИХ 
МЕТАСТАЗІВ РАКУ ПЕРЕДМІХУРОВОЇ ЗАЛОЗИ.  
  
Представлена робота присвячена актуальному питанню сучасної 
медицини – молекулярним механізмам та факторам розвитку кіст-
кових метастазів злоякісних пухлин, зокрема раку передміхурової 
залози. У ході дослідження були проаналізовані положення літера-
турних джерел останніх років щодо процесів формування кісткових 
метастазів раку передміхурової залози та експресії окремих марке-
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рів у її тканині. Зокрема було всебічно розглянуто класичну конце-
пцію seed and soil, котра описує феномен тропності циркулюючих 
метастатичних клітин до певного мікрооточення та викликає розви-
ток специфічних за локалізацією метастазів.  
Були узагальнені та порівняні погляди на молекулярно-
генетичні основи впливу експресії андрогенових рецепторів неоп-
ластичних клітин на розвиток саме остеобластичного типу метаста-
зів, причини та молекулярні механізми розвитку кастраційно-
резистентного раку передміхурової залози. Автори розглянули та 
узагальнили теоретичні знання, що описують участь білків р53, Вах 
та активованої каспази 3 в апоптозі, процеси неоангіогенезу та ре-
моделювання сполучнотканинного компоненту пухлин із залучен-
ням матриксної металопротеїнази 1, особливості присутності кола-
гену 1 типу та іншого остеобластичного маркеру остеонектину в 
неопластичній тканині та роль запалення у процесах метастазуван-
ня. Також було висвітлено функції білків теплового шоку із моле-
кулярними масами 70 та 90 кДа та їх роль у пухлинній та метаста-
тичній тканині.  
Таким чином проведене дослідження доповнює та узагальнює 
дані, що стосуються процесів розвитку кісткових метастазів раку 
передміхурової залози. У ході дослідження було всебічно проаналі-
зовано молекулярно-генетичні особливості раку передміхурової 
залози за його метастатичного поширення. 
Ключові слова: рак передміхурової залози, кісткові метастази, 
імунофенотип, рецептори до андрогенів, неоангіогенез, білки теп-
лового шоку, матриксна металопротеїназа 1, запалення, остеоблас-
тичні маркери, апоптоз.  
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Вступ 
Peculiarities of prostate cancer bone 
metastases  
Prostate cancer (PC), as well as breast cancer, is 
characterized by pronounced osteotropism 
regarding metastases. It is known that 
approximately 80% of metastases to the organs of 
the locomotor apparatus occur due to these 
pathologies [1], while malignant tumors of other 
localizations do not have such tropism [2; 3]. The 
first person, who tried to explain this phenomenon, 
was the English surgeon Stephen Paget, who 
believed that tumor cells are able to "colonize" only 
those organs, which have a favorable 
microenvironment for neoplastic cells. This theory 
is still relevant for tumors that form distant 
metastases [4]. 
In 1928, James Ewing suggested that the 
morphological characteristics of blood and 
lymphatic vessels have a decisive influence on the 
peculiarities of tumor metastasis [4]. 
It is now believed that such characteristics of 
the red bone marrow as high degree of 
vascularization, presence of a significant number of 
biochemical factors (cell adhesion molecules, 
cytokines and chemokines) in conjunction with 
physical factors (low pH, hypoxia, high calcium 
content in the extracellular matrix) contribute to the 
colonization, survival and growth of tumor cells in 
bone tissue [5; 6].  
The vast majority of prostate cancer bone 
metastases are sclerotic, whereas for other 
malignancies (breast cancer, kidney and lung 
cancer) metastases are predominantly osteolitic in 
nature [7; 8]. Despite the fact that PC bone 
metastases may result in osteogenesis, the newly 
formed bone tissue has impaired histoarchitectonics 
and contributes to the appearance of pathological 
fractures [9].  
During metastases of neoplastic PC cells to the 
bone tissue they first cause bone resorption, which 
leads to the release of significant amounts of 
biologically active substances and growth factors, 
in particular insulinlike growth factor (IGF) 1, and 
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stimulates the activity of osteoblasts [10; 11]. It has 
also been shown that prostate cancer increases serum 
level of endothelin-1, which stimulates the 
proliferation of osteoblasts and promotes 
osteogenesis [12; 13].  
Experimental in vivо studies have shown that 
bone mass reduction significantly decreases the 
likelihood of PC bone metastases development [14]. 
There is also indication of the possibility of 
activation of osteblasts by cancer cells through bone 
morphogenetic protein 1 [15]. There is an 
assumption that urokinaselike plasminogen activator, 
just like prostate-specific antigen (PSA) produced by 
the tumor is capable of activating osteoblast through 
hydrolysis of IGF-binding proteins, resulting in 
increased levels of free IGF. PSA is also able to 
cleave parathyroid hormone bound protein, which is 
the promoter of osteoclastogenesis, reducing bone 
resorption [16; 17; 18].  
It is known that sex hormones influence bone 
growth and development [19; 20]. Thus, men with 
low androgen levels show bone mass reduction 
similar to women in menopausal period [21].  
Sclerotic character of PC bone metastases in 
comparison with malignant neoplasms of other 
localizations also indicates association with 
androgens, expression of which can be found in 
osteoblasts [22]. They are important in maintaining 
the mass of the trabecular bones, and are able to 
indirectly inhibit osteoclastogenesis through 
inhibition of the expression of nuclear factor kV 
activator receptors in osteoblasts [23; 24]. Androgens 
are also capable of converting to estrogen with the 
activation of its receptors in osteoclasts and 
osteoblast precursors. All described mechanisms 
cause inhibition of bone resorption and stimulation 
of osteoprotegerin synthesis in osteoblasts. Men with 
low levels of androgens show a bone mass reduction 
similar to women in menopausal period [25]. 
However, the results of studies, conducted by many 
laboratories, differ significantly, not providing a 
complete picture of the initiation and progression of 
PC bone metastases. That is why the aim of this 
study was to analyze the literature data and 
characterize the molecular genetic peculiarities of PC 
bone metastases development.  
Sensitivity to steroid hormones 
Androgens are necessary for the normal 
development and functioning of unaltered prostate, 
as well as the vital activity of PC cells [26]. Their 
action is conditioned by the activation of androgen 
receptors, which are ligand-dependent transcription 
factors. Testosterone, which has the highest 
concentration in blood plasma, is secreted by 
Leydig's cells in the testicles and in a small amount 
(up to 5-10 %) by the adrenal glands [27; 28; 29]. In 
prostate tissue testosterone is converted into 
dehydrotestosterone, a steroid hormone, that has 
more pronounced effects [30]. When androgens 
interact with the corresponding receptors, the 
processes of their dimerization and transport from 
the cytoplasm to the nucleus are activated. Activation 
of various genes, such as KLK2, NKX3-1, STEAP2 
and KLK 3, which encodes PSA synthesis, occurs as 
a result of binding of receptor dimers to the 
corresponding promoter sites of target genes. There 
is also possible interaction with numerous 
coregulatory proteins, like HOXB13 and FOXA1 
[31].  
Prostate cancer is a hormone-dependent disease, 
so the androgen receptors is the primary molecular 
element of the systematic treatment of this disease. 
However, patients with advanced ЗС have tumor 
progression and development of castration-
insensitive prostate neoplasia [32; 33; 34]. That is, 
the level of PC sensitivity to androgens is 
proportional to the degree of its differentiation. 
However, the production of enzymes for the 
synthesis of androgens continues in the tissue of 
androgen-independent PC, as a result their 
concentration in tumor tissue may exceed normal 
level [35]. 
This hormonal resistance is explained by changes 
in androgen receptors, including hyperexpression of 
proteins that are part of androgen receptors (AGR), 
amplification and mutation of AGR genes, as well as 
the formation of so-called AGR variants, or isomers 
[36]. These isomers are fragments of the AGR-
proteins, not capable of binding to AGR domains. 
Although these molecules were found in the 
castration-resistent PC, they do not have a significant 
effect on the function of the unaltered prostate or in 
primary tumors of this gland [37].  
However, today the possibility of a combined 
effect of androgens and estrogens on the prostate 
carcinogenesis processes has been proved. Age-
related involutive changes in the reproductive system 
of men lead to impairment of androgens and estrogen 
ratio: the level of androgens is reduced with age, 
while estrogen level remains constant or even 
increases [38]. Activation of estrogen receptors (ER) 
α in an unaltered prostate leads to increased 
proliferative activity of glandular epithelium and 
inflammation. Instead, activation of ERß has 
antiproliferative and even carcinosuppressive effect, 
and its expression changes dynamically during 
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prostate cancer progression [39; 40]. Although the 
expression of these receptors to estrogen in the tumor 
microenvironement is reduced compared to unaltered 
prostate tissue, higher levels of ERα expression were 
detected in the stroma of highly differentiated 
tumors, compared to low differentiated [41]. R. 
Pisolato et al. (2016) established not only the 
possibility of formation of new ER isoforms, but also 
the variability of their localization, which can 
influence the activation of ERK1/2 signal pathway in 
the prostate cancer RS-3 cell line [42].  
Osteoblastic markers in PC 
Osteonectin (OSN) (SPARC, a basal membrane 
protein, BM-40) is a calcium-binding matrix protein 
with a molecular mass of 32 kDa. [43; 44]. It is a 
glycoprotein with a spiral spatial structure, capable 
of variable glycosylation depending on tissue-
specific expression [45; 46]. 
At one time OSN was considered to be the main 
marker of biomineralized soft tissues due to its 
pronounced concentration in the calcification foci. 
However, studies, conducted by J J.D. Termine et al. 
(1981) demonstrated a much broader model of its 
expression in both mineralized and non-mineralized 
tissues [47]. Typically, OSN expression is associated 
with the presence of fibrillar collagens, such as type I 
collagen. The structure of OSN consists of binding 
domains with both collagen and hydroxyapatite [48; 
49]. So, collagen-binding domain is localized in the 
C-fragment of the OSN molecule, whereas the 
hydroxyapatitetropic is located in the N-region. This 
creates the conditions for its participation in the 
processes of collagen mineralization both during 
osteogenesis and biominerogenesis [47]. OSN 
functions also include regulation of cell proliferation 
and migration, tissue remodeling and angiogenesis 
[50; 51]. 
In addition to osteoid cells, other types of cells, 
present in mineralized tissues, including endothelial 
cells and fibroblasts, demonstrate the ability to 
synthesize OSN [52]. OSN can also be found in 
platelets and macrophages in the foci of chronic 
injury, as well as in endotheliocytes [53; 54; 55]. 
Today, the question of OSN participation in the 
initiation and progression of prostate cancer is 
insufficiently studied, since most of the works are 
aimed at studying its action on the bone tissue 
elements. In the case of PC, OSN has a 
predominantly stimulating effect and causes further 
progression of prostate neoplasia [56], thus 
increasing the aggressiveness of the tumor and its 
metastatic potential. According to Ruela-Arispe M. 
L. et al. (1995), this phenomenon is explained by the 
fact that OSN is able to disrupt the morphology of 
target cells by reducing the number of focal 
intercellular contacts and blocking cell adhesion to 
basal membranes or surrounding cells. The study has 
revealed the absence of OSN in the tissue of 
unaltered prostate and its expression in neoplastic 
cells and extracellular matrix in 30% of PC cases 
[57].  
The studies of N. Burns-Сox et al. (2001) showed 
significant changes in the protein content in the 
stromal component of the tumor in PC: with the 
increase in the PC stage according to Gleeson, the 
collagen content (in particular type I collagen) 
decreases, while in the surrounding unaltered 
prostate tissue, this indicator significantly increases 
compared to the control. However, there is a 
significant intensification of expression of collagen 
synthesis markers in the prostatic neoplasia foci [58].  
There is also an indication of the OSN ability to 
increase the production of matrix metalloproteinases, 
which indirectly influences the processes of PC bone 
metastases, where its increased expression is also 
manifested [59].  
The role of matrix metalloproteinase 1 in PC 
progression 
Matrix metalloproteinase 1 (MMP1) belongs to 
zinc-containing endopeptitases with pronounced 
collagenase activity [60; 61]. Synthesis of this 
enzyme occurs both in neoplastic cells and in tumor 
stroma and is associated with tumor progression, 
prognosis deterioration, invasion and shortening of 
survival time [62]. Its ability to influence epithelial-
mesenchymal transformation of tumor cells and 
modulate intercellular interactions also significantly 
influences invasive potential of the tumor [63; 64; 
65]. It has been demonstrated that inhibition of 
MMP1 synthesis by bone morphogenetic protein 6 
reduces the likelihood of metastases [66]. The ability 
of MMP1 to interact with PAR1 and МАРК 
determines its role in the processes of cell invasion, 
angiogenesis and dissemination [67].  
MMP1 along with ADAMTS-1 (EGF-like 
growth factor) is considered as a predictor of 
osteolysis, which corresponds to the development of 
bone metastases [68]. In their studies, Casimiro S. et 
al. (2013) revealed a relationship between the 
expression of MMP1 and RANK (activator of 
NF-κB receptors) via ERK/cFos and JNK/cJun and 
ММР1 promoter activation. Disabling of these 
pathways leads to a decrease in the number of 
osteoclasts and the intensity of osteolysis. This 
indicates that PC cells synthesize MMP1, which 
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stimulates the development of metastatic phenotype 
of tumor cells [69; 70].  
Heat shock proteins and CP 
Heat shock proteins (HSP) are a group of 
chaperone proteins that take part in the spatial 
organization of the protein and maintain its structure 
during stress, preventing their aggregation [71; 72]. 
At the moment, the most studied are HSPs with a 
molecular weight of 70kDa and 86kDa (Hsp70 and 
Hsp90, respectively), which play a significant role in 
the processes of proliferation, differentiation and 
carcinogenesis [73]. Their participation in 
carcinogenesis and influence on immune response 
modeling, apoptosis inhibition and development of 
resistance to chemotherapeutic agents has led to their 
thorough study [74]. Blocking of apoptosis is 
achieved by binding of high-molecular HSPs with 
caspases and impairment of their activation. This 
creates conditions in the tumor tissue for the 
accumulation of a pool of cells with hidden 
mutations and further tumor progression [75].  
The relationship between the expression of HSPs 
in epithelial malignant tumors and the deterioration 
of prognosis for the patient is also indicated [76]. In 
their study, Li Ni et al. (2010) proved the 
participation of Hsp90 in the process of 
implementation of the effects of androgens in PC 
tumor cells through creation of superchaperone 
complex FKBP51-Hsp90-p23. This complex binds 
with AGR and increases the number of these 
molecules in the cytoplasm, stimulating 
androgendependent transcription and cell growth, 
and reduces Hsp70 concentration [77; 78]. Toshifumi 
Kurahashi et al. (2007) disproves relationship of 
Hsp70 and Hsp90 and PC progression. Instead, he 
thinks that low-molecular-weight HSPs, such as 
Hsp27, can be used as a predictor of biochemical 
recurrence in patients after radical prostatectomy 
[79]. 
Although HSPs are unable to directly influence 
the processes of biomineralization, protein 
conglomerates, in which they are present, are able to 
indirectly influence the biomineralcreation process in 
the human body. Shifa Narula et al. (2017) proved 
the presence of Hsp70 as a matrix protein in the 
urinary system calculi [80]. There is also indication 
of the involvement of this protein and osteopontin in 
the processes of crystal structure modeling of the 
biominerals, reducing their cytotoxic effect [80; 81]. 
According to Erman Chen et al. (2015) Hsp70 
directly affects the differentiation of mesenchymal 
stem cells and is able to stimulate osteogenesis in 
them. This effect is implemented through the 
activation of alcaline phosphatase and ERK-
dependent signaling pathway at its extracellular 
concentrations exceeding 200 ng/ml [82].  
However, Fong-Ngern K. et al. (2016) pointed 
out a direct involvement of Hsp90 in the 
development of urolithiasis. This protein is expressed 
on the apical surface of the tubular epithelium and 
promotes the binding of calcium oxalate to epithelial 
cells by means of a specific Ca2+-binding domain in 
its structure. Moreover, Hsp90 has been detected on 
the surface of endocytic vesicles during 
internalization of calcium crystals, which indicates 
its involvement in this process [83]. This 
macromolecule takes direct part in an intracellular 
calcium homeostasis. The interaction of a specific 
ATP-binding domain in the Hsp90 molecule leads to 
a decrease in the amount of intracellular ATP and a 
decrease in the passage of Са2+ through protein 
kinase C and membrane calcium transport proteins 
(4
th
 isoform). This results in an increase in the 
concentration of calcium inside the cell [84].  
However, low-molecular HSPs may have the 
opposite effect in the bone tissue – dephosphorylated 
Hsp27 inhibits osteocalcin, thereby reducing the 
intensity of mineralization processes in mature 
osteoblasts [85].  
Apoptosis and angiogenesis in prostate cancer 
tissue 
The process of apoptosis activation can be both 
internal and external [86]. The external apoptotic 
pathway is activated by TNF receptors (Fas, 
TRAIL). According to this mechanism, the caspase 8 
activates the caspase pathway with the involvement 
of caspase 3, 6 and 7, which causes apoptosis [87]. 
The internal (mitochondrial) pathway is Bcl-2-
dependent and can be initiated by DNA damage, 
oxidative stress, dysfunction of growth factors, etc 
[88; 89].  
Protein p53 is a tumor suppressor due to its 
ability to regulate the transcription of proapoptotic 
factors and thus initiate cell apoptosis through 
multiple pathogenetic pathways, in particular 
through the cell cycle termination. This protein can 
interact with Bax protein and predetermine increased 
permeability of the outer mitochondrial membrane 
[90; 91]. However, the presence of mutated R53 
protein in the cell leads to dysfunction of the wild 
type of this protein. Thus, changes in the expression 
of this protein lead to disruption of the cell cycle, 
accumulation of neoplastic cell mutations and cancer 
progression [92]. It was shown that the deficiency of 
functional p53 in tumor cells significantly reduces 
the effectiveness of radio- and chemotherapy, and 
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consequently worsens the prognosis of the disease 
[93].  
Activated caspase 3 (Casp3) is one of the key 
enzymes, involved in apoptosis. In its inactive state, 
this protein has a mass of 32 kDa. However, in case 
of its activation by means of aspartate pathway due 
to a cascade of biochemical transformations, P12 and 
P17 subunits are created, which form the activated 
enzyme [94]. Thus, the detection of the activated 
form of Casp3 can be used to assess the levels of 
apoptosis in tissues [95]. In case of apoptosis 
activation via internal pathway (involving proteins 
from the bcl-2 family), occurs activation of Casp3 
with the involvement of cytochrome C and Apaf-1 
with the formation of the complex – apoptosome 
[96].  
Bax protein (or Bcl-2 associated X-protein) is 
related to Bcl-2 associated proteins. Its activation is 
accompanied by its conformational changes, 
destabilization of the mitochondrial membrane by 
the formation of transmembrane pores, release of 
cytochrome C to the cytoplasm and activation of 
oxidative phosphorylation, as well as impairment of 
intracellular calcium homeostasis [97; 98]. That is 
why it is considered as a key link of both apoptotic 
processes and necrosis [99]. In addition, Вах is able 
to indirectly stimulate apoptosis processes by 
activating caspase of the 3-dependent apoptotic 
pathway [100]. Its proapoptotic activity can also be 
mediated due to its ability to inhibit antiapoptotic 
genes, such as Bcl-2 and Bcl-XL [101]. Thus, the 
Bcl-2/Bax system can become a potential therapeutic 
link in the management of malignant tumors by 
stimulating the apoptosis of neoplastic cells [102; 
103]. It was also reported about the possible 
therapeutic effect of Bax expression stimulants in the 
treatment of paclitaxel-resistant breast cancer by the 
means of binding to Bcl-XL and inhibiting its 
antiapoptotic action [104]. However, no studies were 
conducted regarding the influence of itraluminary 
inclusions on the level of Bax expression in prostate 
cancer tissues and its participation in the processes of 
metastasis.  
Angiogenesis is an important part of tumor 
growth and progression. Earlier, an increased 
expression of vascular endothelial growth factor 
(VEGF) in PC tissue was established [105]. Its role 
in the processes of proliferation of endotheliocytes, 
vascular growth, initiation of carcinogenesis and 
metastases has been established [106; 107; 108]. 
Combination of these effects is implemented by 
means of interaction of several forms of this factor 
(VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E 
and PIGF) with tyrosine kinase receptors (VEGFR-1, 
VEGFR-2 and VEGFR-3) [109; 110]. From the 
perspective of carcinogenesis and PC metastasis, the 
most important is the interaction of VEGF-A– 
VEGFR-2. As a result of this interaction, there is a 
cascade of intracellular phosphorylation reactions, 
which result in cell proliferation, their migration and 
survival, as well as pronounced angiogenesis. This is 
conditioned by the activation of molecular 
mechanisms PI3K, Akt/PBK, NF-κB, p38MAPK, 
RAS, MAK and ERK [111]. In vivo studies have 
shown that VEGF in bone tissue has auto- and 
paracrine action. It participates in chemotaxis, 
proliferation and differentiation of osteoblasts, 
modulation of osteolytic function of osteclasts [112]. 
The presence of metastatic PC tissue with high 
VEGF-synthesizing function creates an imbalance 
between the processes of resorption and formation of 
bone tissue with a predominance of the latter, which 
is manifested by development of osteoblastic 
(osteosclerotic) metastases [113; 114]. Thus, 
expression of VEGF by neoplastic tissue creates 
optimal conditions for the formation of osteosclerotic 
PC metastases, stimulates and supports the growth of 
cancer cells, initiates angiogenesis and has a 
transforming effect on the tumor tissue itself [111]. 
The role of inflammation in the development 
of bone metastases 
The role of inflammation in the development and 
progression of prostate cancer due to DNA damage 
(genetic and epigenetic modulation), stimulation of 
cell proliferation and angiogenesis, cytoskeleton and 
extracellular matrix remodeling is proven [115; 116]. 
However, there is another potential impact of 
inflammation on the PC metastasis.  
Initiating stage of the process of PC metastasis 
is the epithelial-mesenchymal transformation – 
morphological transformation of cells due to 
reduction of synthesis of cell adhesion molecules 
[117]. As a result, tumor cells acquire 
characteristics that allow them to migrate from the 
focus of the primary tumor and cause their 
intravasation [118]. This process requires the 
presence of CD68
+
 tissue macrophages. Earlier, it 
was found that their increased number corresponds to 
the worst PC prognosis [119]. Synthesis of mediators 
of inflammation and cytokines, such as TNFα, by 
macrophages and neutrophils causes the 
development of reactions of NF-κB cascade 
mechanisms, which leads to inhibition of E-cadherin 
synthesis and increase of metastatic potential of 
tumors [120]. NF-κB nuclear factor is also associated 
with the release of IL-6 cytokine [121].  
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During inflammation endothelial cells express a 
number of cell adhesion molecules, in particular the 
Р- and Е-selectins, intracellular adhesion molecules 
A and vascular adhesion molecules 1. These 
proteins are ligands of K (C-X-C) (CXCR) 4/6/7 
(CXCR4/6/7) chemokines, αvβ3 integrin, RANK, 
CD44 and annexin 2, expressed by neoplastic cells. 
The interaction of these substances allows cancer 
cells to bind specifically to endotheliocytes, 
accelerating their migration and attachment to 
endotheliocytes of bone tissue vessels [122]. This 
creates conditions for the "recognition" and 
attachment of freely circulating tumor cells to the 
tissue that best corresponds to the 
immunophenotype of these cells, has an optimal 
microenvironment and creates conditions for the 
growth and development of metastases [123]. 
 
Conclusion  
Thus, the development of PC bone metastases is 
a complex process, which is caused by the 
biochemical peculiarities of both tumor cells and 
bone tissue microenvironment. The process of 
metastasis is accompanied by a cascade of 
biological reactions, involving a variety of 
pathological pathways and biological interactions. 
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